Pfizer Inc (PFE)

$27.97 -0.10 (-0.36%)
Market Cap 159.99B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 9.11
Forward PE 9.33
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 23,845,600
Avg Vol 44,625,605
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 84%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Reversal_Levels
Reversal_Levels Aug. 25 at 9:22 AM
Trade update. PFE is on pP signal (partial profits). We will use it to close this trade early at today's Open. Longer term investors can still hold (or sell half), but we try to show some different strategies. We can always pick $PFE back up if it comes down to test its RevL. In the chart we see how PFE is bumping into a double key price level, while PuLL and MoM look toppish. More: https://blog.reversallevels.com/2026/08/trading-journal-aug-25-2026.html (previous: https://x.com/lunatictrader1/status/2077710846394769855 )
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:15 AM
$PFE Pfizer PFE -0.36% ▼ stock is a Buy despite declining revenue, in my view. Shares of the drugmaker have been modestly ahead of the S&P 500 (SPX) in 2026, helped by an upwardly revised revenue guidance as well as a cheap valuation. With a 6.13% dividend yield and a 2026 non-GAAP P/E multiple of 9.43x, PFE stock is indeed one of the most compelling value opportunities in the large-cap healthcare space.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:10 AM
$PFE Why Bulls See a Breakout Ahead The bull case rests on execution. Launched and acquired products grew 22% operationally in Q1 2026, with Padcev up 39% and Nurtec ODT/Vydura up 42%. Pfizer expects 19 pivotal study starts over the next 12 months across oncology, obesity, and immunology. Management is guiding to a high single-digit revenue CAGR from year end 2028 through 2033. If the obesity pipeline hits, our bull-case model reaches $36.17 within a year, and $52.18 over five.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:08 AM
$PFE Our 24/7 Wall St. price target for Pfizer (NYSE:PFE) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07. Our recommendation is buy, with high model confidence of 90%. Pipeline momentum, a re-rated 2026 guide, and a 6.19% dividend yield tip the scale toward a rebound thesis.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:06 AM
$PFE Pfizer (PFE) earns a BUY rating with a $32.36 price target, 15% upside, and a 6.19% dividend yield anchoring the rebound thesis. Pfizer trades at 10x forward earnings, a steep discount to Merck (MRK) at 18x and Bristol Myers Squibb (BMY) at 11x. CEO Albert Bourla beat consensus revenue nine of ten quarters, with 19 pivotal study starts planned across oncology, obesity, and immunology.
0 · Reply
jrh34
jrh34 Aug. 24 at 7:51 PM
$CRDF I would say today's conference was bullish for both NMS and CRDF. There's plenty of money for both companies selling Onvasertib rights to a partner like $PFE - a good day for everyone, well except for anyone short.
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Aug. 24 at 7:24 PM
$PFE nice to see https://finance.yahoo.com/markets/stocks/articles/pfizer-stock-wall-street-sees-150011046.html
0 · Reply
Makingmillions192
Makingmillions192 Aug. 24 at 6:47 PM
$LEXX Success in investing is more of a psychological issue than a math issue. The math is here. The patience is the hard part. If you need a guiding star on why we are on the cusp of transformative success read this: While the market gets distracted by low-volume noise, the fundamentals just got wildly de-risked. Today’s Animal Study #2 data proved DehydraTECH 3.0 delivers staggering absorption gains (+4,552% for Retatrutide, 1.65% bioavailability for Amycretin) in solid oral tablets while outperforming Novo's SNAC using open-source binders. That scientifically validates our entire thesis right before Human Study #7 drops. We aren't just holding for a study readout—we're waiting on multi-week, steady-state human tablet data that could force Big Pharma into major licensing deals. Stay disciplined. $LLY $NVO $PFE $MRK
0 · Reply
doubleuptwice
doubleuptwice Aug. 24 at 5:59 PM
$PFE close above 28.16
2 · Reply
Loudermilk64
Loudermilk64 Aug. 24 at 4:03 PM
$PFE green?
0 · Reply
Latest News on PFE
Pfizer Stock (PFE) Is a Buy despite Declining Revenue

2026-08-24T12:18:00.000Z - 22 hours ago

Pfizer Stock (PFE) Is a Buy despite Declining Revenue

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

2026-08-19T14:35:12.000Z - 5 days ago

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

BNTX MRK MRNA

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

2026-08-16T13:55:21.000Z - 8 days ago

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

VALN

Pfizer (PFE) CEO Buys $1 Million of Company Stock

2026-08-14T18:45:04.000Z - 10 days ago

Pfizer (PFE) CEO Buys $1 Million of Company Stock

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Aug 14, 2026, 1:45 PM EDT - 10 days ago

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Closed Pfizer biopharma facility in Everett gets a new lease on life

Aug 14, 2026, 11:46 AM EDT - 10 days ago

Closed Pfizer biopharma facility in Everett gets a new lease on life

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Aug 14, 2026, 11:11 AM EDT - 10 days ago

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes

2026-08-14T13:47:35.000Z - 10 days ago

Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes

VALN

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Aug 14, 2026, 1:00 AM EDT - 11 days ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

VALN

Pfizer price target lowered to $31 from $35 at Guggenheim

2026-08-07T11:40:49.000Z - 17 days ago

Pfizer price target lowered to $31 from $35 at Guggenheim

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Earnings Call Transcript: Q2 2026

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Earnings release: Q2 2026

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Slides: Q2 2026

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Quarterly report: Q2 2026

Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 20 days ago

Pfizer Post Loss on Higher Revenue

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Aug 4, 2026, 7:13 AM EDT - 20 days ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Aug 4, 2026, 7:12 AM EDT - 20 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4, 2026, 6:52 AM EDT - 20 days ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Aug 4, 2026, 6:45 AM EDT - 20 days ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 7:48 AM EDT - 25 days ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 30, 2026, 6:45 AM EDT - 25 days ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 26 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:48 PM EDT - 4 weeks ago

Pfizer's prostate cancer drug combination gets US FDA priority review

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 22, 2026, 4:30 PM EDT - 4 weeks ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

Jul 21, 2026, 7:10 PM EDT - 4 weeks ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026, 1:39 PM EDT - 5 weeks ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026, 11:23 AM EDT - 6 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 7 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 2 months ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 2 months ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 2 months ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 2 months ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 2 months ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 2 months ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 2 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 2 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 3 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 3 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 3 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 3 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 3 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 3 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 3 months ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Reversal_Levels
Reversal_Levels Aug. 25 at 9:22 AM
Trade update. PFE is on pP signal (partial profits). We will use it to close this trade early at today's Open. Longer term investors can still hold (or sell half), but we try to show some different strategies. We can always pick $PFE back up if it comes down to test its RevL. In the chart we see how PFE is bumping into a double key price level, while PuLL and MoM look toppish. More: https://blog.reversallevels.com/2026/08/trading-journal-aug-25-2026.html (previous: https://x.com/lunatictrader1/status/2077710846394769855 )
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:15 AM
$PFE Pfizer PFE -0.36% ▼ stock is a Buy despite declining revenue, in my view. Shares of the drugmaker have been modestly ahead of the S&P 500 (SPX) in 2026, helped by an upwardly revised revenue guidance as well as a cheap valuation. With a 6.13% dividend yield and a 2026 non-GAAP P/E multiple of 9.43x, PFE stock is indeed one of the most compelling value opportunities in the large-cap healthcare space.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:10 AM
$PFE Why Bulls See a Breakout Ahead The bull case rests on execution. Launched and acquired products grew 22% operationally in Q1 2026, with Padcev up 39% and Nurtec ODT/Vydura up 42%. Pfizer expects 19 pivotal study starts over the next 12 months across oncology, obesity, and immunology. Management is guiding to a high single-digit revenue CAGR from year end 2028 through 2033. If the obesity pipeline hits, our bull-case model reaches $36.17 within a year, and $52.18 over five.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:08 AM
$PFE Our 24/7 Wall St. price target for Pfizer (NYSE:PFE) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07. Our recommendation is buy, with high model confidence of 90%. Pipeline momentum, a re-rated 2026 guide, and a 6.19% dividend yield tip the scale toward a rebound thesis.
0 · Reply
Etiqute
Etiqute Aug. 25 at 8:06 AM
$PFE Pfizer (PFE) earns a BUY rating with a $32.36 price target, 15% upside, and a 6.19% dividend yield anchoring the rebound thesis. Pfizer trades at 10x forward earnings, a steep discount to Merck (MRK) at 18x and Bristol Myers Squibb (BMY) at 11x. CEO Albert Bourla beat consensus revenue nine of ten quarters, with 19 pivotal study starts planned across oncology, obesity, and immunology.
0 · Reply
jrh34
jrh34 Aug. 24 at 7:51 PM
$CRDF I would say today's conference was bullish for both NMS and CRDF. There's plenty of money for both companies selling Onvasertib rights to a partner like $PFE - a good day for everyone, well except for anyone short.
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Aug. 24 at 7:24 PM
$PFE nice to see https://finance.yahoo.com/markets/stocks/articles/pfizer-stock-wall-street-sees-150011046.html
0 · Reply
Makingmillions192
Makingmillions192 Aug. 24 at 6:47 PM
$LEXX Success in investing is more of a psychological issue than a math issue. The math is here. The patience is the hard part. If you need a guiding star on why we are on the cusp of transformative success read this: While the market gets distracted by low-volume noise, the fundamentals just got wildly de-risked. Today’s Animal Study #2 data proved DehydraTECH 3.0 delivers staggering absorption gains (+4,552% for Retatrutide, 1.65% bioavailability for Amycretin) in solid oral tablets while outperforming Novo's SNAC using open-source binders. That scientifically validates our entire thesis right before Human Study #7 drops. We aren't just holding for a study readout—we're waiting on multi-week, steady-state human tablet data that could force Big Pharma into major licensing deals. Stay disciplined. $LLY $NVO $PFE $MRK
0 · Reply
doubleuptwice
doubleuptwice Aug. 24 at 5:59 PM
$PFE close above 28.16
2 · Reply
Loudermilk64
Loudermilk64 Aug. 24 at 4:03 PM
$PFE green?
0 · Reply
Loudermilk64
Loudermilk64 Aug. 24 at 3:47 PM
$PFE going to do another gap up by Wednesday probably…
0 · Reply
Chickenstick1
Chickenstick1 Aug. 24 at 3:40 PM
$PFE Could be a good, much cheaper, way to play the personalized MRNA vaccine for cancer. The co does own some critical IP that allow them to bring a competitor to market.
0 · Reply
AJeaton91
AJeaton91 Aug. 24 at 1:59 PM
$PFE added very lightly here, looking to play the turn around story over the next couple years.
1 · Reply
nimii
nimii Aug. 24 at 1:44 PM
$PFE 😠
0 · Reply
Outcomes
Outcomes Aug. 24 at 1:19 PM
$PFE $MRNA $MRK $JNJ $IBRX ....mRNA BAD. Sudden deaths, myocarditis, turbo-cancers....compromised immunity, etc. SAVE THE CHILDREN. 🙏 https://x.com/ValerieAnne1970/status/2091646664352133205?s=20
0 · Reply
Makingmillions192
Makingmillions192 Aug. 24 at 1:18 PM
$LEXX Holy shit this is massive. • Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study • Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated • Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs $LLY $NVO $PFE $AMGN
0 · Reply
NorthOfSouth
NorthOfSouth Aug. 24 at 11:41 AM
$PFE 28.70 today
1 · Reply
Loudermilk64
Loudermilk64 Aug. 24 at 11:31 AM
$PFE forgot the $TEM tag. They wouldn’t be able to make it without the Tempus and the Personalis. $MRNA $JNJ $MRK .
0 · Reply
Loudermilk64
Loudermilk64 Aug. 24 at 11:29 AM
$PFE it’s been selling around this price for the past year. Maybe the shorts will offer a couple bucks over the 52 wk high, 30?, for all the bag holders?
0 · Reply
Quantumup
Quantumup Aug. 24 at 11:11 AM
Morgan Stanley🏁 $QTTB and said -- We initiate coverage of Q32 Bio (QTTB) with an Overweight rating and a $34 price target. $LLY $PFE ABBV NKTR SNY Here's what Morgan Stanley went on to say in its initiation report: https://x.com/Quantumup1/status/2091845523888079173?s=20
0 · Reply
Outcomes
Outcomes Aug. 24 at 10:01 AM
$IBRX $MRNA $MRK $PFE $JNJ ……🤔 monkey business https://x.com/jsolomonreports/status/2091501968359395399?s=46
2 · Reply
Szepen
Szepen Aug. 24 at 7:54 AM
$SLS If Regal goes under 0,50 HR that will make so much splash... $MRNA and $PFE created an environment that will drive a 100+ opener easily if Regal succeed... The CEO will go to Fox News again for sure...
1 · Reply